Genetic and pharmacological models of cholinergic supersensitivity and affective disorders

Experientia

Volumn 44, Issue 6, 1988, Pages 465-472

  Overstreet, D H ^a   Russell, R W ^a   Crocker, A D ^a   Gillin, J Ch ^a   Janowsky, D S ^b,c  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Acetylcholine; animal model; depression; DFP; Flinders sensitive and resistant lines of rats; genetic selection; supersensitivity

Indexed keywords

ACETYLCHOLINE; AMITRIPTYLINE; APOMORPHINE; ARECOLINE; ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; ESTRADIOL; OXOTREMORINE; PILOCARPINE; SCOPOLAMINE; THYROXINE; TRAZODONE;

AFFECTIVE NEUROSIS; ANIMAL MODEL; CORPUS STRIATUM; DEPRESSION; HIPPOCAMPUS; HUMAN; HYPERADRENOCORTICISM; HYPOTHYROIDISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RAT; REVIEW;

ACETYLCHOLINE; ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; HUMAN; MICE; MICE, INBRED STRAINS; MOOD DISORDERS; MUSCARINE; RATS; RATS, INBRED STRAINS; RECEPTORS, MUSCARINIC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023877094     PISSN: 00144754     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/BF01958920     Document Type: Review

References (97)

1. Depressive disorders: Toward a unified hypothesis
2. Effects of d-amphetamine and scopolamine on activity before and after shock in three mouse strains
3. Depression: the predisposing influence of stress
4. Scopolamine induces an increase in muscarinic receptor level in rat hippocampus
5. Selection for high rates and low rates of avoidance conditioning in the rat
6. Neurotransmitter studies of neuroendocrine pathology in depression
7. Cholinergic mechanisms and anterior pituitary hormone secretion
8. Lithium's effects on muscarinic receptor binding parameters: A relationship to therapeutic efficacy?
9. Antidepressant withdrawal phenomena
10. Antidepressant withdrawal-induced activation (hypomania and mania): Mechanism and theoretical significance
11. Phanmacological and anatomical aspects of cholinergic activation of female sexual behavior
12. Regional 5-HT analysis in Roman high- and low-avoidance rats following MAO inhibition
13. Behavioral, emotional and neurochemical profiles of rats selected for extreme differences in active, two-way avoidance performace
14. Stereotypic hypothermic and central dopaminergic effects of apomorphine in Roman high avoidance and Roman low avoidance rats
15. Recent findings in central dopaminergic and cholinergic neurotransmission of Roman high- and low-avoidance (RHA/Verh and RLA/Verh) rats
16. Differences in the stereotypy response but not the hypomotility response to apomorphine in the Roman high and low avoiding strains of rats
17. Genotypic variation in the dopaminergic inhibitory control of striatal and hippocampal activity in mice
18. Genetically determined cholinergic involvement in morphine-induced behavioral responses in mice
19. A comparison of the effects of morphine withdrawal, thyroxine or thyroidectomy on the sensitivity of anococcygeus muscle to agonists and on serum thyroxine levels in the rat
20. 3H-diazepam binding sites in Roman high- and Roman low-avoidance rats
21. Genetics of the major psychoses: A review
22. Involvement of corticosteroids in supersensitivity produced in rat anococcygeus muscle by morphine withdrawal, thyroidectomy or a single injection of reserpine
23. Effects of acute and chronic administration of antidepressant drugs on the central cholinergic system: Comparison with anticholinergic drugs
24. Differential acquisition of a “working memory” task by the Roman strains of rats
25. An overview of neurobiological comparisons in mouse strains
26. Effets of hippocampal electrical stimulation on long-term memory and on cholinergic mechanisms in three inbred strains of mice
27. A cholinergic-adrenergic hypothesis of mania and depression
28. Acetylcholine and depression
29. Increased vulnerability to cholinergic stimulation in affective disorder patients
30. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress
31. Brain cholinergic systems and the pathogensis of affective disorders
32. Anmal models and human depressive disorders
33. Muscarinic binding in suicides
34. Cushing's syndrome and depression: A prospective study of 26 patients
35. Failure to confirm muscarinic receptors on skin fibroblasts
36. Studies on the role of brain cholinergic systems in the therapeutic mechanism and adverse effects of electroconvulsive therapy and lithium
37. Chronic administration of cholinergic agents: Effects on behavior and calmodulin
38. Learned helplessness and animal models of depression. Prog. Neuro-Psychopharmac.
39. Increased muscarinic receptor binding in rat forebrain after scopolamine.
40. Tolerance to an anticholinergic agent is paralleled by increased binding to muscarinic receptors in rat brain and increased behavioral responses to a centrally active cholinomimetic
41. Genetic influences on cholinergic drug response
42. Genetics of nicotine response in four inbred strains of mice
43. Chronic scopolamine treatment and brain cholinergic function
44. A diallel analysis of nicotine-induced hypothermia
45. Rat lung cholinergic receptor: Characterization and regulation by corticosteroids
46. Effects of scopolamine, pilocarpine and oxotremorine on the exploratory behavior of two psychogenetically selected lines of rats in a complex maze
47. Differential response to cholinergic stimulation in psychogenetically selected rat lines
48. Cognitive functioning in the affective disorders
49. Hormonal effects on hypothalamic neurons: Analysing gene expression and neuromodulatory action
50. Anmal models of depression: An overview
51. Human brain receptor alterations in suicide victims
52. Classical genetic analysis of nicotine-induced seizures and nicotinic receptors
53. Muscarinic cholinergic receptors on skin fibroblasts in familial affective disorder
54. Genetic and sex differences in the cholinergic modulation of thermoregulation
55. Dextroamphetamine and arecoline as pharmacogenetic probes in normal and remitted bipolar patients
56. Behavioral, physiological and neuro-endocrine response to arecoline in normal twins and well state bipolar patients
57. Exploratory activity: Genetic analysis of its modification by scopolamine and amphetamine
58. Sex differences following manipulations of the cholinergic system by DFP and pilocarpine
59. Selective breeding for sensitivity to the anticholinesterase, DFP
60. Brain muscarinic cholinergic receptor binding in Roman high-avoidance and low-avoidance rats
61. Selective breeding for sensitivity to DFP. Effects of cholinergic agonists and antagonists
62. Behavioural plasticity and the cholinergic system
63. Selective breeding for differences in cholinergic function: Sex differences in the genetic regulation of sensitivity to the anticholinesterase, DFP
64. Selective breeding for differences in cholinergic function: Pre-and post-synaptic mechanisms involved in sensitivity to the anticholinesterase, DFP
65. Selective breeding for increased cholinergic function: Development of a new animal model of depression
66. Enhanced elevation of corticosterone following arecoline administration to rats selectively bred for increased cholinergic function
67. Stress-induced immobility in rats with cholinergic supersensitivity
68. Behavioral despair
69. Interaction among central transmitters
70. Estradiol 17β increases the number of muscarinic receptors in hypothalamic nuclei
71. Correlation of muscarinic receptor induction in the ventromedial hypothalamic nucleus with the activation of feminine sexual behavior by estradiol
72. Amtriptyline: long-term treatment elevates beta-adrenergic and muscrinic receptor binding in mouse brain
73. Radial maze performance in three strains of mice: Role of the fimbria/ fornix
74. Regional high affinity3H-choline accumulation in cat forebrain. Selective increase in caudate-putamen after corticosteroid pretreatment
75. Muscarinic supersensitivity of anterior pituitary ACTH and beta endorphin release in major depressive illness
76. Cholinergic challenge in affective illness: Behavioral and neuroendocrine correlates
77. Differential mood effects of arecoline in depressed patients and normal volunteers
78. Selective breeding for sensitivity to DFP. Generalisation of effects beyond criterion variables
79. Mechanisms underlying sensitivity to organophosphorus anticholinesterase compounds
80. Studies on the possible relationship of brain proteins to behavioral sensitivity to DFP
81. Faster cholinergic REM sleep induction in euthymic patients with primary affective illness
82. Cholinergic regulation of mood and REM sleep: A potential model and marker for vulnerability to depression
83. Genetically determined differences in acute responses to diisopropylfluorophosphate
84. Chronic scopolamine treatment increases REM sleep and muscarinic receptor binding during withdrawal
85. Increased uptake of3H-choline by rat superior cervical ganglion: An effect of dexamethasone
86. Changes in brain muscarinic acetylcholine receptors and behavioral responses to atropine and apomorphine in chronic atropine-pretreated rats
87. Genotype-dependent effects of scopolamine and eserine on exploratory behavior in mice
88. Central location of a genotype-dependent cholinergic mechanism controlling exploratory behavior in mice
89. Effects of intrahippocampal injections of methscopolamine and neostigmine upon exploratory behavior in two inbred mouse strains
90. Muscarinic supersensitivity induced by septal lesion or chronic atropine treatment
91. The validity of animal models of depression
92. Motor activity and affective illness. The relationship of amplitude and temporal distribution to changes in affective state